ADVFN US – Market Content Editor
-
Barclays Says Fed Could Reconsider Cuts if Tariff Impact Intensifies
Barclays highlighted that strong second-quarter earnings have helped support equity markets amid ongoing economic uncertainties, but early indications that tariffs may be starting to weigh on U.S. growth could prompt the Federal Reserve to move sooner than expected. “[The] majority of the Q2 earnings is done and results have generally managed to clear a low…
-
BCA Warns Any Dollar Strength “Will Not Last for Long”
According to a recent analysis by BCA Research, the U.S. dollar’s broad trade-weighted index suffered a significant technical breakdown after becoming oversold in the first half of the year. While the dollar may find some short-term support, BCA cautions that any gains “will not last for long.” The firm views the technical breakdown as a…
-
Big Tech Keeps Driving Strong Earnings, Says Barclays
Barclays analysts say Big Tech remains at the heart of U.S. corporate earnings strength, continuing to outperform expectations and driving upward revisions to full-year forecasts for the S&P 500. In a recent U.S. Equity Insights report, the bank stated that “Big Tech continues to defy expectations,” highlighting the group’s average earnings beat of 12%, year-over-year…
-
Gold surges 29% in 2025, outperforming all major asset classes
Gold has stood out as the best-performing asset class so far in 2025, climbing 29% year-to-date and surpassing the returns of leading stock indices, bonds, G10 currencies, and bitcoin, according to a report published Tuesday by UBS. UBS continues to rate gold as “Attractive” within its global asset preferences, emphasizing that hedging strategies remain crucial…
-
Nasdaq Reaches New Record Closing High As Apple Extends Surge
Following the mixed performance seen in the previous session, stocks moved mostly higher over the course of the trading on Friday. With the upward move, the tech-heavy Nasdaq reached a new record closing high. The major averages all finished the day firmly in positive territory. The Nasdaq jumped 207.32 points or 1.0 percent to 21,450.02,…
-
TeraWulf Stock Rises After Blowout Q2 Earnings and Revenue Growth
TeraWulf Inc. (NASDAQ:WULF) shares climbed 4.1% in Friday trading after the digital infrastructure and bitcoin mining firm delivered second-quarter earnings that dramatically surpassed Wall Street expectations. The company posted adjusted earnings of $0.05 per share for the quarter ending June 30, 2025, crushing the consensus forecast of a -$0.06 loss. Revenue reached $47.6 million, slightly…
-
PAR Technology Surpasses Q2 Estimates as Revenue Soars Nearly 44%
PAR Technology Corporation (NYSE:PAR) reported second-quarter results that slightly outpaced analyst forecasts, propelled by a sharp 43.8% year-over-year revenue increase driven by strong uptake of its multi-product solutions. For the quarter ending June 30, 2025, the restaurant and retail tech provider posted adjusted earnings of $0.03 per share, beating the expected $0.02. Revenue climbed to…
-
Sotera Health Shares Climb After Q2 Earnings Surpass Estimates
Sotera Health Co. (NASDAQ:SHC) reported second-quarter results that outperformed analyst expectations, driven by strong gains in its sterilization segment, pushing shares up 2.7% after the announcement. The company, a global leader in sterilization solutions and laboratory testing services, posted adjusted earnings per share of $0.20, beating the forecasted $0.17. Revenue reached $294.3 million, well above…
-
Incannex Shares Surge Following Promising Sleep Apnea Trial Data
Incannex Healthcare Inc. (NASDAQ:IXHL) saw its stock jump 10% on Friday after positive Phase 2 trial results for its obstructive sleep apnea (OSA) treatment, IHL-42X, were announced. The clinical-stage pharmaceutical firm revealed encouraging efficacy data from its RePOSA Phase 2 study, highlighting that 57.6% of patients reported noticeable improvements in their OSA symptoms during exit…
-
Nutriband Shares Climb After FDA Grants Meeting for Fentanyl Patch
Nutriband Inc. (NASDAQ:NTRB) saw its stock rise 8% on Friday following news that the U.S. Food and Drug Administration (FDA) has approved a Type C Meeting for its lead product, AVERSA FENTANYL — an abuse-deterrent fentanyl transdermal system. Scheduled as a virtual face-to-face session on September 18, 2025, the meeting will offer the company feedback…